You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
|
|---|---|
| Published in |
Lancet Oncology, June 2016
|
| DOI | 10.1016/s1470-2045(16)30107-3 |
| Pubmed ID | |
| Authors |
Toni K Choueiri, Bernard Escudier, Thomas Powles, Nizar M Tannir, Paul N Mainwaring, Brian I Rini, Hans J Hammers, Frede Donskov, Bruce J Roth, Katriina Peltola, Jae Lyun Lee, Daniel Y C Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N Sternberg, David F McDermott, Dana T Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E Hutson, Sumanta Pal, Robert J Motzer, METEOR investigators |
X Demographics
The data shown below were collected from the profiles of 28 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 14% |
| United Kingdom | 2 | 7% |
| Spain | 2 | 7% |
| Turkey | 1 | 4% |
| Colombia | 1 | 4% |
| Canada | 1 | 4% |
| Czechia | 1 | 4% |
| France | 1 | 4% |
| Venezuela, Bolivarian Republic of | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 13 | 46% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 57% |
| Practitioners (doctors, other healthcare professionals) | 6 | 21% |
| Scientists | 4 | 14% |
| Science communicators (journalists, bloggers, editors) | 2 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 492 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | <1% |
| United States | 1 | <1% |
| Belgium | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 487 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 78 | 16% |
| Other | 67 | 14% |
| Student > Ph. D. Student | 51 | 10% |
| Student > Bachelor | 41 | 8% |
| Student > Master | 39 | 8% |
| Other | 87 | 18% |
| Unknown | 129 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 201 | 41% |
| Biochemistry, Genetics and Molecular Biology | 36 | 7% |
| Agricultural and Biological Sciences | 30 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 24 | 5% |
| Nursing and Health Professions | 9 | 2% |
| Other | 39 | 8% |
| Unknown | 153 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 156. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 June 2023.
All research outputs
#266,905
of 26,017,215 outputs
Outputs from Lancet Oncology
#313
of 6,958 outputs
Outputs of similar age
#5,161
of 360,081 outputs
Outputs of similar age from Lancet Oncology
#8
of 161 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,958 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,081 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 161 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.